PARP Inhibition Restores Erectile Function by Suppressing Corporal Smooth Muscle Apoptosis in Diabetic Rats

Journal of Sexual Medicine

Volumn 8, Issue 4, 2011, Pages 1072-1082

  Li, Wen Ji ^a   Zhou, Juan ^a   Li, Bao ^a   Wang, Hao ^a   Peng, Yu Bing ^a   Wang, Zhong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Animal Model; Apoptosis; Diabetes; Erectile Dysfunction; Poly(ADPribose) Polymerase; Smooth Muscle

Indexed keywords

3 AMINOBENZAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; COLLAGEN SYNTHESIS; CORPUS CAVERNOSUM; DIABETES MELLITUS; ENZYME ACTIVATION; ENZYME INHIBITION; ERECTILE DYSFUNCTION; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PENIS; PENIS ERECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; SMOOTH MUSCLE; STREPTOZOCIN DIABETES; TREATMENT RESPONSE;

EID: 79953316405     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.02176.x     Document Type: Article

References (43)

1. Saenz de Tejada I, Angulo J, Cellek S, Gonzalez-Cadavid N, Heaton J, Pickard R, Simonsen U. Pathophysiology of erectile dysfunction. J Sex Med 2005;2:26-39.
2. Costabile RA. Optimizing treatment for diabetes mellitus induced erectile dysfunction. J Urol 2003;170:S35-8.
3. Corona G, Mannucci E, Petrone L, Balercia G, Paggi F, Fisher AD, Lotti F, Chiarini V, Fedele D, Forti G, Maggi M. NCEP-ATPIII-defined metabolic syndrome, type 2 diabetes mellitus, and prevalence of hypogonadism in male patients with sexual dysfunction. J Sex Med 2007;4:1038-45.
4. Burchardt T, Burchardt M, Karden J, Buttyan R, Shabsigh A, de la Taille A, Ng PY, Anastasiadis AG, Shabsigh R. Reduction of endothelial and smooth muscle density in the corpora cavernosa of the streptozotocin induced diabetic rat. J Urol 2000;164:1807-11.
5. Traish AM, Toselli P, Jeong SJ, Kim NN. Adipocyte accumulation in penile corpus cavernosum of the orchiectomized rabbit: A potential mechanism for veno-occlusive dysfunction in androgen deficiency. J Androl 2005;26:242-8.
6. Wespes E, Goes PM, Schiffmann S, Depierreux M, Vanderhaeghen JJ, Schulman CC. Computerized analysis of smooth muscle fibers in potent and impotent patients. J Urol 1991;146:1015-7.
7. Azadzoi KM. Vasculogenic erectile dysfunction: Beyond the haemodynamic changes. BJU Int 2006;97:11-6.
8. Alici B, Gumustas MK, Ozkara H, Akkus E, Demirel G, Yencilek F, Hattat H. Apoptosis in the erectile tissues of diabetic and healthy rats. BJU Int 2000;85:326-9.
9. Jesmin S, Sakuma I, Salah-Eldin A, Nonomura K, Hattori Y, Kitabatake A. Diminished penile expression of vascular endothelial growth factor and its receptors at the insulin-resistant stage of a type II diabetic rat model: A possible cause for erectile dysfunction in diabetes. J Mol Endocrinol 2003;31:401-18.
10. Yamanaka M, Shirai M, Shiina H, Tanaka Y, Tsujimura A, Matsumiya K, Okuyama A, Dahiya R. Diabetes induced erectile dysfunction and apoptosis in penile crura are recovered by insulin treatment in rats. J Urol 2003;170:291-7.
11. Yamanaka M, Shirai M, Shiina H, Tanaka Y, Enokida H, Tsujimura A, Matsumiya K, Okuyama A, Dahiya R. Vascular endothelial growth factor restores erectile function through inhibition of apoptosis in diabetic rat penile crura. J Urol 2005;173:318-23.
12. Park K, Ryu KS, Li WJ, Kim SW, Paick JS. Chronic treatment with a type 5 phosphodiesterase inhibitor suppresses apoptosis of corporal smooth muscle by potentiating Akt signalling in a rat model of diabetic erectile dysfunction. Eur Urol 2008;53:1282-8.
13. Li WJ, Park K, Paick JS, Kim SW. Chronic treatment with an oral Rho-kinase inhibitor restores erectile function by suppressing corporal apoptosis in diabetic rats. J Sex Med 2010 Mar 2 [Epub ahead of print] doi: 10.1111/j.1743-6109.2010.01724.x.
14. Kovanecz I, Ferrini MG, Vernet D, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Pioglitazone prevents corporal veno-occlusive dysfunction in a rat model of type 2 diabetes mellitus. BJU Int 2006;98:116-24.
15. Mokini Z, Marcovecchio ML, Chiarelli F. Molecular pathology of oxidative stress in diabetic angiopathy: Role of mitochondrial and cellular pathways. Diabetes Res Clin Pract 2010;87:313-21.
16. Allen DA, Yaqoob MM, Harwood SM. Mechanisms of high glucose-induced apoptosis and its relationship to diabetic complications. J Nutr Biochem 2005;16:705-13.
17. Maiese K, Chong ZZ, Shang YC. Mechanistic insights into diabetes mellitus and oxidative stress. Curr Med Chem 2007;14:1729-38.
18. Kiss L, Szabo C. The pathogenesis of diabetic complications: The role of DNA injury and poly(ADP-ribose) polymerase activation in peroxynitrite-mediated cytotoxicity. Mem Inst Oswaldo Cruz 2005;100(suppl):29-37.
19. Pacher P, Szabo C. Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: Endothelial dysfunction, as a common underlying theme. Antioxid Redox Signal 2005;7:1568-80.
20. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, Brownlee M. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 2003;112:1049-57.
21. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002;54:375-429.
22. Mathews MT, Berk BC. PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2. Arterioscler Thromb Vasc Biol 2008;28:711-7.
23. Kovacs K, Toth A, Deres P, Kalai T, Hideg K, Gallyas F, Jr, Sumegi B. Critical role of PI3-kinase/Akt activation in the PARP inhibitor induced heart function recovery during ischemia-reperfusion. Biochem Pharmacol 2006;71:441-52.
24. Szanto A, Hellebrand EE, Bognar Z, Tucsek Z, Szabo A, Gallyas F, Jr, Sumegi B, Varbiro G. PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol. Biochem Pharmacol 2009;77:1348-57.
25. Wang SJ, Wang SH, Song ZF, Liu XW, Wang R, Chi ZF. Poly(ADP-ribose) polymerase inhibitor is neuroprotective in epileptic rat via apoptosis-inducing factor and Akt signaling. Neuroreport 2007;18:1285-9.
26. Yu SW, Andrabi SA, Wang H, Kim NS, Poirier GG, Dawson TM, Dawson VL. Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci U S A 2006;103:18314-9.
27. Tapodi A, Debreceni B, Hanto K, Bognar Z, Wittmann I, Gallyas F, Jr, Varbiro G, Sumegi B. Pivotal role of Akt activation in mitochondrial protection and cell survival by poly(ADP-ribose)polymerase-1 inhibition in oxidative stress. J Biol Chem 2005;280:35767-75.
28. Nangle MR, Cotter MA, Cameron NE. Poly(ADP-Ribose) Polymerase inhibition reverses nitrergic neurovascular dysfunctions in penile erectile tissue from streptozotocin-diabetic mice. J Sex Med 2010;10:3396-403.
29. Wan ZH, Li WZ, Li YZ, Chen L, Li GH, Hu WF, Peng S, Yu JJ, Guo F. Poly(ADP-Ribose) polymerase inhibition improves erectile function in diabetic rats. J Sex Med 2010 Aug 30 [Epub ahead of print] doi: 10.1111/j.1743-6109.2010.01963.x.
30. Kim GT, Chun YS, Park JW, Kim MS. Role of apoptosis-inducing factor in myocardial cell death by ischemia-reperfusion. Biochem Biophys Res Commun 2003;309:619-24.
31. Jin HR, Kim WJ, Song JS, Piao S, Tumurbaatar M, Shin SH, Choi MJ, Tuvshintur B, Song KM, Kwon MH, Yin GN, Koh GY, Ryu JK, Suh JK. Intracavernous delivery of synthetic angiopoietin-1 protein as a novel therapeutic strategy for erectile dysfunction in the type II diabetic db/db mouse. J Sex Med 2010;7:3635-46.
32. Wang Y, Dawson VL, Dawson TM. Poly(ADP-ribose) signals to mitochondrial AIF: A key event in parthanatos. Exp Neurol 2009;218:193-202.
33. Kovanecz I, Rambhatla A, Ferrini M, Vernet D, Sanchez S, Rajfer J, Gonzalez-Cadavid N. Long-term continuous sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats. Int J Impot Res 2008;20:202-12.
34. Peralta-Leal A, Rodriguez-Vargas JM, Aguilar-Quesada R, Rodriguez MI, Linares JL, de Almodovar MR, Oliver FJ. PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases. Free Radic Biol Med 2009;47:13-26.
35. Zaremba T, Curtin NJ. PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med Chem 2007;7:515-23.
36. Shimoda K, Murakami K, Enkhbaatar P, Traber LD, Cox RA, Hawkins HK, Schmalstieg FC, Komjati K, Mabley JG, Szabo C, Salzman AL, Traber DL. Effect of poly(ADP ribose) synthetase inhibition on burn and smoke inhalation injury in sheep. Am J Physiol Lung Cell Mol Physiol 2003;285:L240-9.
37. Garcia Soriano F, Virag L, Jagtap P, Szabo E, Mabley JG, Liaudet L, Marton A, Hoyt DG, Murthy KG, Salzman AL, Southan GJ, Szabo C. Diabetic endothelial dysfunction: The role of poly(ADP-ribose) polymerase activation. Nat Med 2001;7:108-13.
38. Southan GJ, Szabo C. Poly(ADP-ribose) polymerase inhibitors. Curr Med Chem 2003;10:321-40.
39. Bryant HE, Helleday T. Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents. Biochem Soc Trans 2004;32:959-61.
40. Obrosova IG, Drel VR, Pacher P, Ilnytska O, Wang ZQ, Stevens MJ, Yorek MA. Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: The relation is revisited. Diabetes 2005;54:3435-41.
41. Minchenko AG, Stevens MJ, White L, Abatan OI, Komjati K, Pacher P, Szabo C, Obrosova IG. Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J 2003;17:1514-6.
42. Chiu J, Farhangkhoee H, Xu BY, Chen S, George B, Chakrabarti S. PARP mediates structural alterations in diabetic cardiomyopathy. J Mol Cell Cardiol 2008;45:385-93.
43. Pandya KG, Patel MR, Lau-Cam CA. Comparative study of the binding characteristics to and inhibitory potencies towards PARP and in vivo antidiabetogenic potencies of taurine, 3-aminobenzamide and nicotinamide. J Biomed Sci 2010;17(suppl):S16.